Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review

Sophie Pilleron, Helen Gower, Maryska Janssen-Heijnen, Virginia Signal, Jason Gurney, Eva JA Morris, Ruth

Cunningham, Diana Sarfati

Results

Age pattern in colon and lung cancer survival

Colon cancer (Table 4)

Patient characteristics

Respecting sex, Dickman et al. showed that the difference in 1-year RS between patients aged 45-59 and those

aged 75 years or older with localised cancer was equivalent across sexes (absolute difference = 7 percentage

points in both sexes). However, survival disparities between age groups were slightly greater for females than for

males with regional spread (9 vs. 5 points), and much larger in females than in males with distant disease (24 vs.

19 points)⁵³. Majek et al. found no age disparity in 5-year RS in both males and females with cancer of the right

colon²⁹. However, females with left colon cancer had a slightly greater difference in 5-year RS between younger

and older patients than males (9 vs. 7 points). In the study of Mariotto et al., age disparities in 5-year RS were

similar in males and females (8-9 points)54

Clinical characteristics

Regarding stage at diagnosis, three studies used the Tumor, Nodes, Metastases (TNM) classification^{16,26,31}, and

one study used the Surveillance, Epidemiology, and End Results Program (SEER) staging system⁵³. Using the

TNM classification, Yancik et al. showed that age disparities in 1-year OS were highest for patients with unknown

stage, similar across stages I-III and greater for those with stage IV cancer²⁶. Van den Broek et al. showed similar

age disparities in 5-year RS for stages I and II¹⁶. However, the age disparities were highest for patients with stage

III cancer and minimal for those with stage IV cancer. Interestingly, van Steenbergen et al. reported better 5-year

RS in the oldest age group among those who have survived 3 or 5 years after cancer diagnosis, compared to

middle-aged patients³¹. Using the SEER staging system, age disparities in 1-year RS were shown to be the greatest

for patients with distant cancer (19 points in males and 24 in females), and similar in localised and regional cancers

(7 and 5 points, respectively, in males; 7 and 9 points, respectively, in females)⁵³. However, there was no clear pattern between age disparities in 5-year RS and stage at diagnosis. In males with regional cancer, the oldest age group had better survival than the 45-59 year age group, while there was no age disparity in males with distant cancer. For females, the age disparities were greatest for patients with regional cancer (10 points), while there was no age disparity for those with localized cancer.

Concerning lymph node involvement, Nedrebø et al. found greater age disparities in survival when positive nodes were present compared to when they were not (absolute difference = 15.5 vs. 3.8 points)²⁸. In two other studies, age disparities in survival were larger in patients who had fewer than 12 nodes examined compared to patients who had 12 or more nodes examined^{32,33}.

About sub-sites, Dickman et al. showed no age disparity in survival in patients with cancer of the caecum or the ascending colon⁵³. However, older patients with cancer of the transverse or the descending colon had lower survival than middle-aged patients. The largest age disparities in survival were seen for cancers categorised into « other parts of the colon » (25-point difference). Park et al. revealed a similar magnitude of age disparities in patients with cancer of the distal and those with cancer of the proximal colon (12-13 points)³⁰. When restricted to patients with stage IV cancer, age disparities were smaller for patients with cancer of the distal colon compared to cancer of the proximal colon (9 vs. 12 points). Hur et al. reported similar age disparities regardless of the cancer sub-site (15-17 points)³⁶.

Regarding treatment, three studies focused on chemotherapy^{20,27,34}, and one on surgery¹⁷. In the three chemotherapy studies, time zero (*i.e.* from which the survival time is calculated) was either the cancer diagnosis date or not mentioned. Brungs et al. compared adjuvant oxaliplatin doublet chemotherapy (OD) vs. fluoropyrimidine monotherapy (FM)²⁰. The 1-year mortality rate and OS were similar in patients below or above the age of 70. However, age disparities in 3- and 5-year survival were bigger for the FM group than for the OD group (13 vs. 10 points at 3 years, and 7 vs. 3 points at 5 years). Hines et al. showed larger age disparities in the 5-year mortality rate in patients who did not receive chemotherapy than for those who did³⁴. Conversely, van Steenbergen et al. found greater age disparities in 3- and 5-year OS in patients who received chemotherapy²⁷. However, among those who did not receive chemotherapy, the oldest age group had a better 3-year OS than middle-aged patients, and there was no longer a difference in survival at 5 years. Kolfschoten et al. studied 30-day postoperative mortality

after resection and looked at the role of male gender, American Society of Anesthesiologists score ≥ 3 (ASA-III+), Charlson comorbidity score ≥2, metastatic disease and hemicolectomy¹⁷. In patients who underwent an elective surgery, all individual factors with the exception of comorbidity influenced age disparities, with higher mortality rates in the 80+ age group compared to the <70 age group. The greatest age disparities were observed in patients with metastatic cancer; the 30-day postoperative mortality rates were between 0-3% in patients younger than 80 and 10% in those older. The age disparities in mortality rates increased as the number of risk factors increased. In patients who underwent a non-elective surgery, age disparities in mortality rates were the lowest in those without risk factors (around 2% in <70 years vs. 6-7% 80+), intermediate in those with a ASA III+ score (around 14% vs. 21%), and highest in patients who underwent a hemicolectomy (around 1% in <70 vs. 18-19% in 80+). Age disparities increased with the cumulative number of risk factors.

Aquina et al. found that age disparities in 1-year mortality was significantly greater in patients with complications and sepsis after surgery than for patients without ³⁵, and van den Schans et al. suggested that age disparities in 5-year OS were greater among those with chronic obstructive pulmonary disease (COPD), than those free of COPD at the time of cancer diagnosis ²¹.

<u>Lung cancer</u> (Table 5)

Patient characteristics

Regarding sex, Wingo et al. did not show any age difference in survival across sexes whatever the stage at diagnosis or the race³⁸. Dickman et al. revealed greater age disparities in 1-year RS in females with lung cancer regardless of the stage at diagnosis⁵³. However, females with localized lung cancer had greater age disparities in 5-year RS than males (48 vs. 31 points). Results suggested greater age disparities in males than in females with regional cancer (11 vs. 5 points), while the same age difference across sexes was seen in patients with distant cancer. They also observed greater age disparities in females with adenocarcinomas than in males (19 vs. 13 points) and a similar age difference across sexes for squamous cell carcinoma and small cell carcinoma. Mariotto et al. showed the absolute difference in 5-year RS between the middle-aged group and the oldest age group was slightly greater in females than in males with stages I-III cancer, regardless of the cancer type (SCLC or NSCLC). In patients with stage IV cancer, females and males had similar age disparities (2-3 points). Regarding the 5-year, age disparities were slightly greater in females than in males regardless of the level of comorbidity. Eberle et al.

showed slightly greater age disparities in 5-year RS in females than in males (12.3 vs. 8.6 points)⁴⁵. Ries et al. observed larger age disparities in 5-year RS in females than in males, but only for those with stage II cancer (14 vs. 9 points)³⁷. Sigel et al. found smaller age disparities in 5-year RS in females who underwent a resection than in males (0.4 vs. 5.7 points)⁴⁰. Amongst unresected patients, females aged 80 years and older had a better 2-year RS than those aged below 60 (-4.2 points), while the age disparities in males were not significant (2.3 points). Janssen-Heijnen et al. found slightly greater age disparities in 1-year RS in males with SCLC compared to females (21 vs. 18 points)¹⁹. However, when looking at the 3- and 5- year RS, females showed greater age disparities in survival than males.

Chang et al. investigated survival by socioeconomic status (SES) in advantaged and disadvantaged neighbourhoods⁴¹. In advantaged neighbourhoods, there was no age difference in 5-year OS in patients with low SES, but there were differences of 6 and 7 points between age groups for patients with high and moderate SES, respectively. In disadvantaged neighbourhoods, the age disparities were the greatest for patients with high SES (13 points). In patients with moderate SES, the oldest patients had a better 5-year OS than younger patients (-3 points), while there was a 6-point difference between younger and older patients with low SES.

Regarding race/ethnicity, Wingo et al. showed the age disparities in 5-year RS were lower in black patients with local cancer, compared to white patients, for both sexes, however these differences were not seen in patients with advanced cancer. Although South-Asians living in the UK had better survival than non-South Asians, Maringe et al. found that the difference in 1- and 5-year RS between South Asians aged 45-54 years and those aged 65-69 years old (10.6 and 8.3 points, respectively) was much greater than that observed in non-South Asians (4.9 and 1.7 points, respectively)⁵².

Clinical characteristics

Out of twenty, thirteen studies presented survival data by age group and stage at diagnosis^{18,37–39,43,46,47,49–51,53,54}. Eight used the TNM classification^{18,37,46–51}, three studies the SEER staging system^{38,43,53}, one used both systems⁵⁴, and one study another categorisation system¹⁹. Overall, the age disparities in RS and CSS were highest in the early cancer stages and minimal in the most advanced stages, regardless of the classification system. However, Schulkes et al. showed the same age disparities in 1-year OS for stage I and stage IV disease (19-20 points)⁵⁰.

Van der Drift et al. reported lower age disparities in 5-year RS for stage II compared to stage I and lower age disparities in 3-year RS for stage IIIa compared to stage IIIb, regardless of the treatment strategy¹⁸. The difference in age disparities between stages varied across treatment strategies in two other studies ^{48,49}.

Dickman et al. reported no age difference in 5-year RS in patients with small cell carcinoma, but they revealed a 13-14-point difference between patients aged 45-59 years old and those aged 75 years or older with squamous cell carcinoma and adenocarcinoma ⁵³. One study suggest that age disparities in 5-year RS were slightly greater in patients with stages I-III NSCLC than in those with SCLC ⁵⁴. However, the absolute difference in 5-year RS was around 2 points for patients with stage IV cancer regardless of the cancer type.

About comorbidity, Mariotto et al. showed that, for cancer with localised or regional spread, age disparities in 5-year OS were lower in patients with severe comorbidities than in those with no comorbidity. ⁵⁴ This difference was not visible in patients with distant cancer.

Six studies presented survival by treatment group^{18,42,44,48,49,51}. Only results of Langer et al. could be compared between treatment strategies; the other studies being at high risk of immortal time bias (inappropriate definition or no definition of time zero) ^{18,42,48,49,51}. They showed that age disparities in 1- and 2-year OS were negligible and comparable in both bevacizumab-carboplatin-paclitaxel group and carboplatin-paclitaxel group (1-2 points).⁴⁴